Study of Ondansetron in the Prevention of Sleep Syncope: The Nineth Prevention of Syncope Trial (POST9) (POST9)
Sleep Syncope
About this trial
This is an interventional treatment trial for Sleep Syncope focused on measuring Ondansetron
Eligibility Criteria
Inclusion Criteria: Syncope according to the American College of Cardiology Guidelines 2017 ≥1 Sleep Syncope in the year preceding enrolment ≥-2 points on the Calgary Syncope Symptom Score for Structurally Normal Hearts Age ≥ 18 years with informed consent. Exclusion Criteria: An inability to give informed consent pregnancy, unwilling or unable to use adequate birth control while on study drug QT interval exceeding 500 ms in the absence of correctable factors.
Sites / Locations
- University of Calgary
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Ondansetron
Placebo
ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
Matching placebo will be identical in appearance to the active treatment pill.